The stock is down 1% to $116.14 after hitting $113.38 earlier in the morning.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta could be down on patient death in FDA database, says RBC Capital
- Leerink remains bullish on Sarepta, views EMBARK study results favorably
- Sarepta announces topline results from EMBARK study
- Sarepta’s Elevidys launch remains strong with solid beat, says JPMorgan
- Sarepta reports preliminary Q4 net product revenue $638.2M
Questions or Comments about the article? Write to editor@tipranks.com